scholarly journals PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
A. J.M. Ferreri ◽  
V. Tarantino ◽  
G. Cabras ◽  
F. Ferrara ◽  
P. L. Zinzani ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Prognostic Factors ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cns Involvement ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Central Nervous System Involvement in Patients with Diffuse Large-B Cell Lymphoma: A Retrospective Analysis of a Single Center in Brazil.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 5029-5029
Author(s):  
Talita Rocha ◽  
Maeva Pinto ◽  
Sergio Costa Fortier ◽  
Igor Campos ◽  
Roberto Paes ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Developed Countries ◽  
Stage Iii ◽  
Cns Involvement ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract Abstract 5029 Background Relapse in the central nervous system (CNS) after initial treatment of diffuse large-B cell lymphoma (DLBCL) is an uncommon but serious complication. This retrospective study of a single institution in a Latin American country investigated the incidence of CNS involvement in patients with DLBCL and compared it with results in developed countries. Patients and methods A total of 134 patients treated for DLBCL from January 2001 to April 2008 were retrospectively analyzed for incidence of secondary CNS involvement of lymphoma. Results Twenty six (19,4 %) patients of this cohort had used rituximab as first line treatment and nine (6,7%) had done IT chemoprophylaxis. Seventy (52%) were stage III and IV. Forty seven (35%) had high intermediate or high international prognostic index. Nine of 134 (6,7%) developed CNS disease after a median observation of 36 months. The median time for the CNS relapse or progression was 7,7 months after diagnostic and all but one patient died despite the treatment proposed. Among the 9 patients that relapsed, seven (77,7 %) had parenquimal CNS involvement. Seven (77,7%) had stage III or IV disease. One (11,1 %) had bone marrow involvement. Two (22,2%) received IT chemoprophylaxis and 3 (33,3%) had used rituximab. Discussion and Conclusion We describe here our cases and emphasize that as we know, this is the only Brazilian study investigating this kind of involvement. Different than expected, we found a similar CNS infiltration compared to developed countries cohorts. This suggests that CNS disease is probably related to biologic features than circumstantial issues normally present in developing countries such as late diagnoses and treatment. The evaluation of the risk factors for CNS involvement had not been done due to the small cohort. Disclosures No relevant conflicts of interest to declare.

CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study

2019 ◽  
Vol 91 (7) ◽  
pp. 35-40
Author(s):  
A U Magomedova ◽  
A E Misyurina ◽  
J K Mangasarova ◽  
L G Gorenkova ◽  
O V Margolin ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cns Involvement ◽  
Chemotherapy Drugs ◽  
Leptomeningeal Involvement ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Aim of the issue was to determine indications for intratecal chemotherapy drugs administration to prevent relapse of diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement. Materials and methods. Since January 2009 to December 2018 102 patients with primary nodal DLBCL over 18 years old were treated in the National Research Center for Hematology, Moscow, Russian Federation. Diagnosis were established in all cases according to histological and immunohistochemical studies which made it possible to exclude the transformation of mature B-cell lymphoma into DLBCL. Results. Isolated leptomeningeal involvement of CNS in the debut of the disease was detected in 1 (0.98%) out of 102 patients with DLBCL. Focal brain tissue involvement was not detected in any patient. More than half of the patients (54%) had a high risk of disease recurrence or progression with CNS involvement: in 8 (7.8%) patients had kidney/adrenal involvement, in the same proportion - bone marrow involvement, paranasal sinuses involvement - in 5 (4.9 %), epidural space - in 7 (6.9%) and breast - in 5 (4.9%) of patients. In 82 (80%) patients, a non-GCB (postgerminal differentiation of B-cell analog) molecular subtype of DLBCL was determined. Conclusion. The introduction of chemotherapy drugs into the spinal canal is recommended in isolated cases of leptomeningeal involvement of CNS at the time of DLBCL onset and is carried out according to standard recommendations. Prevention of relapse with involvement of central nervous system using intratecal chemotherapy in patients with nodal form of DLBCL is not indicated due to the absence of cases with disease progression or recurrence into CNS when patients were treated with R-m-NHL-BFM-90, R-DA-EPOCH and R-CHOP protocol.

scholarly journals T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma

Rare Tumors ◽  
2015 ◽  
Vol 7 (4) ◽  
pp. 160-162 ◽  
Author(s):  
Pooja Advani ◽  
Jason Starr ◽  
Abhisek Swaika ◽  
Liuyan Jiang ◽  
Yushi Qiu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Central nervous system relapse in diffuse large B-cell lymphoma: analysis of risk factors and a new prognostic model

2015 ◽  
Vol 26 ◽  
pp. vii85
Author(s):  
Yusuke Kanemasa ◽  
Tatsu Shimoyama ◽  
Yuki Sasaki ◽  
Sawada Takeshi ◽  
Eisaku Sasaki ◽  
...  
Keyword(s):  
Risk Factors ◽  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Prognostic Model ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Central Nervous System Relapse ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document